Granules India (532482) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 was impacted by a voluntary pause in manufacturing and distribution at the Gagillapur facility following a US FDA inspection that resulted in six Form 483 observations; corrective actions and third-party reviews were initiated, and operations resumed in October in a staggered manner.

• Gross margins improved, driven by higher formulation sales and a favorable product mix, despite revenue and profit declines.

• Healthy cash flow from operations was maintained, with new product launches and approvals in the US and Europe expected to drive near-term growth.

• Unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2024, were approved and released, with no material misstatements identified by statutory auditors.

• R&D spend increased year-over-year, focusing on CNS, ADHD, oncology, and fermentation technology.

Financial highlights

• Q2 FY25 consolidated revenue was ₹11,798.65 million, down from ₹11,880.01 million in Q2 FY24; standalone revenue was ₹8,519.50 million, down from ₹10,079.28 million.

• Gross margin rose to 62% from 51.7% in Q2 FY24, driven by a favorable product mix and lower raw material costs.

• EBITDA for the quarter was ₹2,033 million (21% of sales), down 5% year-over-year; PAT was ₹972 million, down 5% year-over-year.

• Cash flow from operations was ₹2,007 million in Q2 FY25.

• CapEx for the quarter was ₹1,324 million, mainly invested in Granules Life Sciences.

Outlook and guidance

• Growth in the near term will be led by new launches from the GPI site in the US and Europe, with a spillover impact from the Gagillapur slowdown expected to lessen in Q3.

• API and PFI demand, especially for paracetamol, is expected to improve in Q3 and normalize by Q4.

• Continued investment in R&D and product pipeline, with emphasis on innovation and sustainability.

• Four additional US launches are planned for the remainder of FY25, with further approvals expected in Q4.

• Focus remains on expanding formulation sales and strengthening presence in North America and other key markets.